PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Curcumin Modestly Lowers HOMA-IR in Overweight Adults; Other Compounds Show Little Effect

curcumingreen tea extractresveratrolomega-3 fatty acidsinsulin resistanceHOMA-IRC-reactive proteinobesityoverweightsystematic reviewmeta-analysisdietary supplementsendocrinology Endocrinology / Diabetes / Obesity

Background Information

Curcumin may help combat insulin resistance in obesity.

Obesity is linked to insulin resistance and inflammation, impacting diabetes risk and cardiovascular health. Curcumin significantly reduced insulin resistance measured by HOMA-IR (MD = -0.30, p = 0.019). Green tea extract had a non-significant CRP reduction. Potential for curcumin as an adjunct therapy in managing insulin resistance in obesity, though results are limited by study biases and variability. Curcumin shows promise for reducing insulin resistance in overweight individuals, but more consistent research is needed.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Nichele S, Prates LM, Busetto L

Citation: Nichele S, Prates LM, Busetto L Effects of Bioactive Compound Supplementation on Insulin Resistance and Systemic Inflammation in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. 2026;18(21). doi:10.3390/nu18213638

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.